In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Merck gets rights to Santen's tafluprost; Santen later re-acquires European rights

Executive Summary

Santen Pharmaceutical (ophthalmic therapies) has granted Merck & Co. exclusive marketing rights in Western Europe (excluding Germany), North and South America, and Africa to its tafluprost for open-angle glaucoma and ocular hypertension.
Deal Industry
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Marketing-Licensing

Related Companies